ID   88-2
AC   CVCL_RA75
DR   Wikidata; Q54605455
RX   PubMed=1306323;
RX   PubMed=7817386;
RX   PubMed=12111518;
CC   Population: Japanese.
CC   Doubling time: 1.5 days (PubMed=7817386); 36.0 +- 2.1 hours (PubMed=12111518).
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_RA76 ! 88-2F
OI   CVCL_RA77 ! 88-2FA
OI   CVCL_RA78 ! 88-2T
SX   Male
AG   47Y
CA   Cancer cell line
DT   Created: 05-03-18; Last updated: 10-04-25; Version: 6
//
RX   PubMed=7817386; DOI=10.1620/tjem.173.217;
RA   Kobayashi, Shunsuke
RA   Okada, Shinichiro
RA   Yoshida, Hiroyuki
RA   Hasumi, Toru
RA   Sato, Nobuyuki
RA   Inaba, Hirohisa
RA   Nakada, Tasaku
RA   Fujimura, Shigefumi
RT   "Syalil-SSEA1(SLX) levels in supernatant of cultured human lung
RT   carcinoma cell lines.";
RL   Tohoku J. Exp. Med. 173:217-229(1994).
//
RX   PubMed=1306323; DOI=10.1620/tjem.168.375;
RA   Kobayashi, Shunsuke
RA   Fujimura, Shigefumi
RT   "Characterization and the clinical application of cultured human
RT   pulmonary carcinoma cells.";
RL   Tohoku J. Exp. Med. 168:375-386(1992).
//
RX   PubMed=12111518; DOI=10.1007/s005950200110;
RA   Kobayashi, Shunsuke
RA   Noda, Masashi
RA   Isogami, Katuhiko
RA   Hasumi, Toru
RT   "c-myc amplification and enhancement of sensitivity to cytosine
RT   arabinoside: an in vitro and in vivo study on four sublines
RT   established from a pulmonary adenocarcinoma.";
RL   Surg. Today 32:608-617(2002).
//